Sign In
Buy SVRA
$5.74
-0.290 (-4.81%)
At Close: Jul 13, 2026
Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
08:41pm, Monday, 23'rd Nov 2020
Savara is a rare lung disease company whose lead asset, Molgradex, failed to meet its primary endpoint in the Phase 3 IMPALA trial. Since that time, Savara has met with the FDA and has designed a new
